The Heart Hospital Baylor Plano
Welcome,         Profile    Billing    Logout  
 138 Trials 
403 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Brown, David W
AFFECTS, NCT02973126: Heartflow

Active, not recruiting
3
270
US
FFRct and SPECT
Baylor Research Institute
Cardiovascular Abnormalities
07/22
07/22
NCT04072354 / 2019-000470-36: A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Completed
3
463
Europe, US, RoW
SEP-363856 50mg, SEP-363856 75mg, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
05/23
09/23
NCT05779241: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

Completed
3
83
US
LYN-005, Risperidone, Risperdal
Lyndra Inc.
Schizophrenia, Schizoaffective Disorder
11/23
12/23
ASPIRE, NCT03907046: Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Recruiting
3
700
US
Apixaban, Eliquis, Aspirin
Yale University, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage, Atrial Fibrillation
04/27
04/27
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)

Recruiting
3
630
Canada, US, RoW
ANX007, Sham Administration
Annexon, Inc.
Geographic Atrophy
10/26
10/27
NCT04740671 / 2020-005364-57: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed
3
410
Europe, US, RoW
HLX04-O, ranibizumab
Shanghai Henlius Biotech
Age Related Macular Degeneration
12/24
12/24
NCT04109950 / 2019-000696-16: A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

Terminated
3
463
Europe, US, RoW
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.
Schizophrenia
11/23
11/23
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/24
09/24
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated
3
83
Europe, Canada, Japan, US
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.
Depressive Episodes, Bipolar I Depression
10/23
10/23
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/29
12/29
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Active, not recruiting
2
350
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
05/25
GION, NCT06178055: A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)

Active, not recruiting
2
75
US
KUS121 high dose, KUS121 low dose, Sham procedure
Kyoto Drug Discovery and Development Co., Ltd.
Central Retinal Artery Occlusion
03/25
12/25
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Recruiting
2
150
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Diabetic Macular Edema (DME)
11/25
12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Recruiting
2
180
Japan, US, RoW
KHK4951, Aflibercept Injection
Kyowa Kirin Co., Ltd.
Neovascular Age-Related Macular Degeneration (nAMD)
11/25
12/25
MAGIC, NCT05681884: Safety and Efficacy of Faricimab in Patients With NPDR

Active, not recruiting
2
179
US
Faricimab
Greater Houston Retina Research, Genentech, Inc.
Non-Proliferative Diabetic Retinopathy
03/26
04/26
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Recruiting
2
146
Europe, US, RoW
Iptacopan (LNP023), Placebo
Novartis Pharmaceuticals
Age-Related Macular Degeneration
10/26
10/26
PRISM, NCT05197270: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Recruiting
1/2
215
US
4D-150 IVT, Aflibercept IVT
4D Molecular Therapeutics
Neovascular (Wet) Age-Related Macular Degeneration
11/25
11/26
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD

Completed
1
21
US
AM712(ASKG712)
AffaMed Therapeutics Limited
Neovascular Age-related Macular Degeneration
11/24
11/24
NCT05057377: Estimating Highest Capacity Performance During Evaluation of Walking for Individuals With Traumatic Brain Injury

Completed
N/A
16
US
Standard Overground Assessment, Robotic Safety-Environment Assessment
The University of Texas Medical Branch, Galveston
Brain Injuries, Traumatic
08/22
08/22
RPNI, NCT04530526: Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface

Completed
N/A
25
US
Regenerative Peripheral Nerve Interface
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Post-Mastectomy Chronic Pain Syndrome
06/23
09/23
i-SIGHT, NCT05447650: Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration

Active, not recruiting
N/A
95
US
i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham
i-Lumen Scientific, Inc.
Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
06/25
06/25
NCT05934773: Post-Brain Injury Walking and Balance Recovery Program

Recruiting
N/A
20
US
KineAssist robotic treadmill
The University of Texas Medical Branch, Galveston, The Moody Foundation
Acquired Brain Injury, Stroke, Traumatic Brain Injury
12/25
12/25
NPC-QIC, NCT02852031: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting
N/A
1000
Europe, Canada, US
Collaborative Learning Network
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
05/26
05/28
Grayburn, Paul A
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Smith, Robert C
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
ReChord, NCT02803957: Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair

Recruiting
N/A
585
US
NeoChord DS1000, Surgical Mitral Valve Repair
NeoChord
Mitral Valve Insufficiency
07/22
07/27
SITRAL, NCT02830204: Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification () Study

Completed
N/A
25
US
Mitral Valve Replacement with Sapien3, MVR
Baylor Research Institute, Edwards Lifesciences
Mitral Annular Calcification
01/23
09/23
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Recruiting
N/A
1400
Europe, US, RoW
Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation
Medtronic Vascular
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
11/26
11/29
INTERMENTAL, NCT05118828: Guided Internet-based Interventions in Primary Care Effectiveness-implementation Randomized Controlled Trial

Active, not recruiting
N/A
1000
Europe
Guided internet-based cognitive behavioural therapy, Treatment as usual in Prompt Mental Health Care (TAU-PMHC)
Norwegian Institute of Public Health, Norwegian Directorate of Health, University of Bergen, Göteborg University, University of Tromso, Sussex Partnership NHS Foundation Trust
Anxiety, Mild to Moderate Depression
08/24
06/26
Reshape-HF2, NCT02444338: A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation

Completed
N/A
505
Europe, RoW
MitraClip, standard of care
University Medical Center Goettingen, University Medical Center Goettingen
Mitral Valve Insufficiency
04/24
04/24
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
NCT06611579: Clinical Study of the InQB8 TTVR System

Not yet recruiting
N/A
50
US
Transcatheter Tricuspid Valve Replacement, inQB8 MonarQ Transcatheter Tricuspid Valve Replacement System
inQB8 Medical Technologies, LLC
Tricuspid Valve Regurgitation
10/26
10/29
ENRAPTUS, NCT04396379: Epicardial Mitral Touch System for Mitral Insufficiency

Not yet recruiting
N/A
10
US
Implant an epicardial device to reshape the mitral valve annulus
Mitre Medical Corp., BSWRI Cardiac Imaging Core Lab (CICL)
Ischemic Mitral Regurgitation, Functional Mitral Regurgitation
12/24
12/27
NCT03382457: Clinical Study of Edwards Cardioband FIT Valve Repair System

Recruiting
N/A
55
US
Transcatheter Tricuspid Valve Repair, Edwards Cardioband Tricuspid Valve Repair
Edwards Lifesciences
Tricuspid Regurgitation
12/26
12/31
Measure, NCT04430972: Immune Responsiveness and Outcome After Aortic Valve Surgery

Not yet recruiting
N/A
150
Europe
Aortic valve replacement
Barts & The London NHS Trust, University College, London
Aortic Valve Disease, Surgery--Complications, Immune System Disorder
09/25
09/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Brinkman, William B
PORTICO IDE, NCT02000115: Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

Recruiting
N/A
1150
US, RoW
Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
Abbott Medical Devices
Aortic Valve Stenosis
10/19
07/25
SURE-AVR, NCT02679404: Sorin Universal REgistry on Aortic Valve Replacement

Terminated
N/A
2758
Europe, Canada, US, RoW
Corcym S.r.l
Aortic Valve Disease, Aortic Stenosis
03/21
03/21
NCT01194362: A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease

Active, not recruiting
N/A
105
US
Baylor Research Institute
Aortic Valve Disease
12/22
12/22
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
RelayBranch, NCT03214601: Early Feasibility Study of the Thoracic Stent-Graft System

Active, not recruiting
N/A
30
US
penetrating atherosclerotic ulcer, aorta branch cardiovascular implant, Relay Branch System, system, endovascular graft, aortic aneurysm treatment
Bolton Medical
Thoracic Aorta Aneurysm, Aneurysm, Ruptured, Aortic Aneurysm
09/23
08/28
ROSS, NCT06352671: Prospective Long-Term Outcomes of a Standardized Ross Procedure

Recruiting
N/A
225
US
Baylor Research Institute
Ross Procedure (Pulmonary Autograft Replacement)
12/25
01/26
NCT06305078: Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study

Active, not recruiting
N/A
30
US
Personalized ADHD Medication Experiment
Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
05/25
05/25
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

Active, not recruiting
N/A
150
Japan, US
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
03/24
03/28
PERSEVERE, NCT05174767: - a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

Active, not recruiting
N/A
115
US
AMDS
Artivion Inc., Syneos Health
Acute Aortic Dissection
12/23
12/29
TITAN:COMMENCE, NCT02860364: Comparing Hypothermic Temperatures During Hemiarch Surgery

Recruiting
N/A
282
Canada, US
Hypothermic circulatory arrest
Ottawa Heart Institute Research Corporation
Thoracic Aortic Disease
02/25
09/25
TITAN:SvS, NCT03536312: Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

Recruiting
N/A
610
Canada, US
Thoracic Aortic Surgery
Ottawa Heart Institute Research Corporation, University of Calgary
Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
05/25
05/26
PS-IDE, NCT03322033: Feasibility of Endovascular Repair of Ascending Aortic Pathologies

Recruiting
N/A
20
US
Valiant PS-IDE Stent Graft
Baylor Research Institute, Medtronic
Dissection of Thoracic Aorta
01/27
01/28
Gable, Dennis R
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
NCT06586021: Evaluation of the Aortoseal™ for Sealing and Fixation of AAA Endovascular Grafts to Aortic Wall

Recruiting
N/A
25
US
Aortoseal Endostapling System
Endoron Medical
Abdominal Aortic Aneurysm (AAA)
09/29
11/29
ADVANCE, NCT05378347: Endurant Stent Graft System vs Excluder Endoprothesis: Trial

Recruiting
N/A
550
Europe, Japan, US, RoW
Medtronic Endurant II or Endurant IIs Stent Graft System, Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Medtronic Cardiovascular
Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
05/27
05/31
GREAT, NCT01658787: Global Registry for Endovascular Aortic Treatment

Active, not recruiting
N/A
4600
Europe, US, RoW
Endovascular aortic repair
W.L.Gore & Associates
Multiple Pathologies
06/27
06/27
TiGER, NCT04246463: Terumo Aortic Global Endovascular Registry

Recruiting
N/A
1000
Europe, US
Thoracic, Abdominal, Custom Device, Illiac Artery
Vascutek Ltd., Bolton Medical
Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
11/29
11/30
IMPROVE-AD, NCT06087029: IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Recruiting
N/A
1100
US
TEVAR, Guideline directed medical therapy and surveillance of dissection
Duke University, The University of Texas Health Science Center, Houston, State University of New York - Downstate Medical Center, Oregon Health and Science University, National Heart, Lung, and Blood Institute (NHLBI)
Type B Aortic Dissection
06/30
06/30
Venermo, Maarit
DELICATVE, NCT03340246: Delayed or Immediate Local Treatment of Veins

Active, not recruiting
N/A
140
Europe
Delayed sclerotherapy, Immediate phlebectomy
Helsinki University Central Hospital
Varicose Veins Leg
12/20
12/22
NCT04737941: Finnish Venous Ulcer Study (FINNULCER Study)

Recruiting
N/A
248
Europe
Endothermal Ablation, Foam Sclerotherapy
Oulu University Hospital, Helsinki University Central Hospital
Venous Ulcer
03/25
03/26
ADVANCE, NCT05378347: Endurant Stent Graft System vs Excluder Endoprothesis: Trial

Recruiting
N/A
550
Europe, Japan, US, RoW
Medtronic Endurant II or Endurant IIs Stent Graft System, Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Medtronic Cardiovascular
Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
05/27
05/31
Johnson, Melissa
NCT03975829 / 2018-004459-19: Pediatric Long-Term Follow-up and Rollover Study

Active, not recruiting
4
165
Europe, Canada, Japan, US, RoW
dabrafenib, DRB436, trametinib, TMT212
Novartis Pharmaceuticals, Novartis Pharma AG
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
05/26
05/26
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
NCT04471415 / 2020-002770-27: Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Terminated
2a
61
Europe, US, RoW
DRP-104, atezolizumab
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
03/23
03/23
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
NCT05275673: A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Terminated
2
7
US
sapanisertib, CB-228
Calithera Biosciences, Inc
Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung, NFE2L2 Gene Mutation
03/23
03/23
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Completed
2
46
US
Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab
SCRI Development Innovations, LLC, Genentech, Inc.
Non-Small Cell Lung Cancer, Solid Tumor
08/24
08/24
NCT04410796: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Recruiting
2
571
US
Osimertinib, Carboplatin, Pemetrexed
Memorial Sloan Kettering Cancer Center, AstraZeneca, Guardant Health, Inc.
Metastatic Non-small Cell Lung Cancer
05/25
05/25
SOLACE-Kids, NCT03474965 / 2017-001747-12: Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

Active, not recruiting
2
118
Europe, Canada, US, RoW
Crizanlizumab, SEG101
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
01/25
01/25
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Active, not recruiting
2
83
US
efineptakin alfa, NT-I7, Atezolizumab, Tecentriq
NeoImmuneTech, Roche Pharma AG
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
09/24
03/25
NSCLC, NCT05948462: Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer () Who Progressed on Single-agent Lorlatinib

Withdrawn
2
15
US
Lorlatinib, Lorbrena, Lorviqua, Cisplatin or Carboplatin, Platinol (Cisplatin), Paraplatin (Carboplatin), Pemetrexed, Alimta, Pemfexy, Ciambra
SCRI Development Innovations, LLC, Pfizer
Lung Cancer, Non-small Cell Lung Cancer
03/25
09/25
TIGOS-LS, NCT06773910: BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer

Not yet recruiting
2
250
NA
BMS-986489, Durvalumab
SCRI Development Innovations, LLC, Bristol-Myers Squibb
Limited Stage Small Cell Lung Cancer
05/32
09/32
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
NCT05127590 / 2021-003829-30: RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Active, not recruiting
1b/2
50
Europe, US, RoW
RBN-2397, Pembrolizumab, Keytruda
Ribon Therapeutics, Inc., Ribon Therapeutics, Inc.
Advanced Squamous Non-Small Cell Lung Carcinoma
11/23
12/23
IMC-C103C-101, NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Withdrawn
1/2
75
Europe, US
IMC-C103C, Atezolizumab, TECENTRIQ
Immunocore Ltd
Select Advanced Solid Tumors
09/23
09/23
NCT04442126 / 2021-000441-41: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Terminated
1/2
52
Europe, US, RoW
NM21-1480
Numab Therapeutics AG
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
02/24
02/24
HPN328-4001, NCT04471727: A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/)

Recruiting
1/2
232
US
MK-6070, HPN328, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
02/26
02/26
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Hourglass Oct 2024 - Dec 2024 : Data for late-line NSCLC
Recruiting
1/2
727
Europe, Canada, US, RoW
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
02/26
08/26
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
MDX-2001-101, NCT06239194: Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Recruiting
1/2
115
US
MDX2001
ModeX Therapeutics, An OPKO Health Company
Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
08/28
02/29
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
STX-241 FIH, NCT06567015: Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Recruiting
1/2
171
Europe, US, RoW
STX-241
Pierre Fabre Medicament
Non-small Cell Lung Cancer (NSCLC)
11/27
07/30
(MARGARET), NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Recruiting
1/2
202
Japan, US
TAS0953/HM06
Helsinn Healthcare SA, ICON Clinical Research
RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
03/25
09/25
NCT04657068: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Recruiting
1/2
547
Europe, US
ART0380, Gemcitabine, Gemzar, Irinotecan, Camptosar, Camptothecin-11
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
06/25
06/25
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Active, not recruiting
1/2
273
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
06/25
06/25
NCT05435339 / 2021-006692-42: A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy

Terminated
1/2
31
Europe, US
GEN1053
Genmab, BioNTech SE
Solid Tumor, Adult
05/24
05/24
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Hourglass Nov 2024 - Dec 2024 : Initial data from at least one additional arm of the Phase 2a portion
Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
NCT05821777: A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Recruiting
1/2
190
Europe, US
LB101
Centessa Pharmaceuticals (UK) Limited, LockBody Therapeutics Ltd
Advanced Solid Tumor
01/27
01/27
TAS3351, NCT05765734: A Study of in NSCLC Patients With EGFRmt

Recruiting
1/2
200
Europe, Japan, US, RoW
TAS3351 oral administration
Taiho Oncology, Inc.
Non-Small Cell Lung Cancer
12/27
12/27
NCT03421353: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Hourglass Jan 2019 - Dec 2020 : Data from P1b/2 trial of Imfinzi in combination with AZD9150 for NSCLC
Completed
1
76
US
AZD9150, Durvalumab, MEDI4736, Cisplatin, 5-Flourouracil, 5-FU, Carboplatin, Gemcitabine, Nab-paclitaxel
AstraZeneca
Advanced Solid Tumours
01/20
03/24
CI-8993-101, NCT04475523: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

Completed
1
26
US, RoW
CI-8993
Curis, Inc.
Solid Tumor
05/23
05/23
NCT04053673: Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Recruiting
1
130
Europe, US
RBN-2397
Ribon Therapeutics, Inc.
Solid Tumor, Adult
06/23
07/23
NCT04660929: CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Active, not recruiting
1
48
US
CT-0508, Pembrolizumab, Keytruda
Carisma Therapeutics Inc
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
12/24
12/24
NCT03894618: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Completed
1
49
Europe, Canada, US
SL-279252
Shattuck Labs, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
05/23
05/23
SURPASS, NCT04044859: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Checkmark Results from SURPASS trial for MAGE-4 positive tumors
Sep 2022 - Sep 2022: Results from SURPASS trial for MAGE-4 positive tumors
Checkmark Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Nov 2019 - Nov 2019: Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Recruiting
1
120
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Adaptimmune, ICON plc
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
12/25
04/37
NCT03522142: A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Active, not recruiting
1
84
Europe, US
INCB081776, INCMGA00012, retifanlimab
Incyte Corporation
Advanced Solid Tumors
04/25
04/25
 

Download Options